# Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

> **NCT02773355** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 27 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** liraglutide 3.0 mg

## Key facts

- **NCT ID:** NCT02773355
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-16
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773355, "Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02773355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*